Reply to Office Action Dated: June 20, 2008

Reply Date: December 2, 2008

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

1. (Currently Amended) A method for inhibiting the growth of androgen-dependent prostate cancer tumor cells in a human comprising administering to a human having androgen-dependent prostate cancer an effective amount of a compound having the structure:

$$R_{9}$$
 R_{10}
 R_{10}
 R_{10}
 R_{10}
 R_{2}
 R_{2}
 R_{3}
 R_{3}
 R_{4}

wherein R₄ and R₅ are H,

wherein R_1 , R_2 , R_3 , R_6 , R_7 , R_9 and R_{10} are independently an unsubstituted C_1 - C_3 alkyl group, and,

wherein R₈ is an OH;

or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) A method for inhibiting the growth of androgen-dependent prostate cancer tumor cells in a human comprising administering to a human having androgen-dependent prostate cancer an effective amount of a compound according to the structure:

$$CH_3$$
 CH_3
 CH_3
 CH_3

or a pharmaceutically acceptable salt thereof.

3-4. (Canceled)

Reply to Office Action Dated: June 20, 2008

Reply Date: December 2, 2008

5. (Currently Amended) A method of delaying the progression of androgen-dependent prostate cancer in a human comprising administering to a human having androgen-dependent prostate cancer an effective amount of a compound having the structure:

$$R_9$$
 R_{10}
 R_{10}
 R_{10}
 R_{10}
 R_{10}
 R_{10}
 R_{10}
 R_{2}
 R_{2}
 R_{3}
 R_{3}
 R_{4}

R₄ and R₅ are H,

wherein R_1 , R_2 , R_3 , R_6 , R_7 , R_9 and R_{10} are independently an unsubstituted C_1 - C_3 alkyl group, and,

wherein R₈ is an OH;

or a pharmaceutically acceptable salt thereof.

6. (Currently Amended) A method of delaying the progression of androgen-dependent prostate cancer in a human comprising administering to a human having androgen-dependent prostate cancer an effective amount of a compound having the structure:

$$H_3C$$
 CH_3
 CH_3
 CH_3
 CH_3

or a pharmaceutically acceptable salt thereof.

- 7. (Canceled)
- 8. (Currently Amended) A method of preventing the recurrence of androgen-dependent prostate cancer in a human comprising administering to a human who has had or presently has androgen-dependent prostate cancer an effective amount of a compound having the structure:

$$R_{9}$$
 R_{10}
 R_{10}
 R_{10}
 R_{10}
 R_{10}
 R_{10}
 R_{2}
 R_{2}
 R_{3}
 R_{4}

Reply to Office Action Dated: June 20, 2008

Reply Date: December 2, 2008

wherein R₄ and R₅ are H,

wherein R_1 , R_2 , R_3 , R_6 , R_7 , R_9 and R_{10} are independently an unsubstituted C_1 - C_3 alkyl group, and.

wherein R₈ is an OH;

or a pharmaceutically acceptable salt thereof.

9. (Currently Amended) A method of preventing the recurrence of androgen-dependent prostate cancer comprising administering to a human who has had or presently has androgen-dependent prostate cancer an effective amount of a compound having the structure:

$$H_3C$$
 CH_3
 CH_3
 CH_3
 CH_3

or a pharmaceutically acceptable salt thereof.

- 10. (Canceled)
- 11. (Withdrawn) A method for the treatment in a patient of an androgen-mediated disorder remediable by contacting an anti-androgen compound with an androgen receptor, comprising the step of administering to the patient an effective amount of:
 - (a) an anti-androgen compound having the formula:

$$\begin{array}{c} R_{9} \\ R_{8} \\ R_{7} \\ R_{6} \\ R_{5} \\ R_{4} \end{array}$$

wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_9 and R_{10} are independently a substituted or unsubstituted C_1 - C_3 alkyl group or H; R_8 is an OH; or

- (b) a pharmaceutically acceptable salt of said compound.
- 12. (Withdrawn) A method according to claim 11 wherein said compound reversibly binds to an is an antagonist of the androgen receptor.

Reply to Office Action Dated: June 20, 2008

Reply Date: December 2, 2008

13. (Withdrawn) A method according to claim 11 wherein said condition is selected from the group consisting of hirsutism, acne, seborrhea, Alzheimer's disease, androgenic alopecia, hyperpilosity, benign prostatic hypertrophy, adenomas or neoplasias of the prostate, treatment of benign or malignant tumor cells containing the androgen receptor, modulation of VEGF expression for use as antiangiogenic agents, osteoporosis, suppressing spermatogenesis, libido, cachexia, endometriosis, polycystic ovary syndrome, anorexia, androgen-related diseases and conditions, male and female sexual dysfunction and infertility.

- 14. (Withdrawn) A method according to claim 11 wherein said condition is a neoplasia of the prostate.
 - 15. (Withdrawn) A method according to claim 11, wherein said compound has the formula:

$$CH_3$$
 CH_3
 CH_3
 CH_3

- 16. (Withdrawn) A method according to claim 11 wherein said compound is characterized by a water solubility greater than that of vitamin E.
 - 17. (Withdrawn) A pharmaceutical composition comprising:
 - (a) a compound having the formula:

$$R_{9}$$
 R_{10}
 R_{10}
 R_{10}
 R_{10}
 R_{2}
 R_{2}
 R_{3}
 R_{3}
 R_{4}

wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_9 and R_{10} are independently a substituted or unsubstituted C_1 - C_3 alkyl group or H; R_8 is an OH; or

- (b) a pharmaceutically acceptable salt of said compound; and
- (c) a pharmaceutically-acceptable carrier.

Reply to Office Action Dated: June 20, 2008

Reply Date: December 2, 2008

18. (Withdrawn) A pharmaceutical composition according to claim 17 wherein said compound has the formula:

$$H_3C$$
 CH_3
 CH_3
 CH_3
 CH_3

- 19. (Withdrawn) A method of providing nutraceutical benefits to a patient comprising the step of administering to the patient a nutraceutical composition including:
 - (a) a compound having the formula:

$$R_9$$
 R_{10}
 R_{10}
 R_{10}
 R_{10}
 R_{2}
 R_{3}
 R_{4}

wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_9 and R_{10} are independently a substituted or unsubstituted C_1 - C_3 alkyl group or H; R_8 is an OH; or

- (b) a pharmaceutically acceptable salt of said compound; and
- (c) a pharmaceutically-acceptable carrier.
- 20. (Withdrawn) A method according to claim 19 wherein said compound has the formula:

- 21. (Withdrawn) A method according to claim 19 wherein said nutraceutical composition further comprises an immune boosting agent, anti-inflammatory agent, anti-oxidant agent, or a mixture thereof.
 - 22. (Withdrawn) A nutraceutical composition comprising:

Reply to Office Action Dated: June 20, 2008 Reply Date: December 2, 2008

(a) a compound having the formula:

$$R_{9}$$
 R_{10}
 R_{10}
 R_{10}
 R_{10}
 R_{2}
 R_{2}
 R_{3}
 R_{4}

wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₉ and R₁₀ are independently a substituted or unsubstituted C₁-C₃ alkyl group or H; R₈ is an OH; or

- (b) a pharmaceutically acceptable salt of said compound; and
- (c) a pharmaceutically-acceptable carrier.
- 23. (Withdrawn) A nutraceutical composition according to claim 22 wherein said compound has the formula:

$$H_3C$$
 CH_3
 CH_3
 CH_3
 CH_3

24. (Withdrawn) A nutraceutical composition according to claim 22 further comprising an immune boosting agent, anti-inflammatory agent, anti-oxidant agent, or a mixture thereof.